Novo Nordisk submits higher Wegovy dose to the European Medicines Agency for approval
 Denmark’s Novo Nordisk (NOVOb.CO), opens new tab said on Tuesday it had submitted a new, higher dose of its obesity treatment Wegovy to the European Medicines Agency for approval, with one in three trial participants achieving 25% or more weight loss.
Novo Nordisk said in a statement it aimed to make the higher dose available throughout the European Union.
“This marks another significant milestone in the company’s goal to provide a broad portfolio of innovative and person-centric solutions to support people living with obesity,” it said.
